文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

危重患者的经静脉肾活检:安全性与诊断阳性率

Transvenous Renal Biopsy of Critically Ill Patients: Safety and Diagnostic Yield.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论单中心回顾性队列显示,ICU急性肾损伤患者经静脉肾活检诊断阳性率96.3%,出血并发症轻微且无需特殊处理,无操作相关死亡。

该单中心回顾性观察性队列纳入2002年1月至2018年2月在一家26床法国三级ICU内接受经静脉肾活检的全部80例患者,评估安全性与诊断阳性率。77例(96.3%)获得组织学诊断,急性肾小管坏死最常见(23例,29.9%),47例(58.7%)发现可能可治疗的病因。4例(5%)出现肾周血肿、2例(2.5%)出现肉眼血尿,均无需特殊处理;无死亡与活检相关,ICU死亡率7.5%,90天死亡率10%。作者结论认为,对于存在出血风险因素的精选危重急性肾损伤患者,经静脉肾活检安全且诊断阳性率高。

要点

  • 80例ICU急性肾损伤患者经静脉肾活检,77例(96.3%)获得组织学诊断,急性肾小管坏死最常见(23例,29.9%)。
  • 47例(58.7%)通过活检发现可能可治疗的病因,提示该操作可提供改变治疗决策的信息。
  • 活检时合并0、1、2、3项出血风险因素(抗血小板治疗、血小板减少<150 G/L、预防或治疗性抗凝)者分别为7例(8.8%)、37例(46.2%)、31例(38.7%)、5例(6.3%)。
  • 肾周血肿4例(5%)、肉眼血尿2例(2.5%),均无需特殊处理;无死亡与经静脉肾活检相关。
  • ICU死亡6例(7.5%),90天死亡8/80(10%);活检至死亡中位间隔38天(四分位距19.7-86天)。

适用人群与场景

  • 2002年1月至2018年2月在一家26床法国三级ICU内接受经静脉肾活检的全部危重患者,共80例(男/女性别比0.95,平均±SD年龄47.3±18.3岁)。
  • 患者为存在出血风险因素(如抗血小板治疗、抗凝或凝血障碍)的急性肾损伤危重患者,具体纳入与排除标准原文未报告。

研究设计与关键结果

  • 研究类型:单中心、回顾性、观察性队列研究,纳入80例ICU内接受经静脉肾活检的患者。
  • 主要结局:77例(96.3%)获得组织学诊断,急性肾小管坏死最常见(23例,29.9%),47例(58.7%)发现可能可治疗的病因。
  • 出血风险因素分布:活检时合并0、1、2、3项因素(抗血小板治疗、血小板减少<150 G/L、预防或治疗性抗凝)者分别为7例(8.8%)、37例(46.2%)、31例(38.7%)、5例(6.3%)。
  • 安全性:肾周血肿4例(5%)、肉眼血尿2例(2.5%),均无需特殊处理;无死亡与经静脉肾活检相关。
  • 预后:ICU死亡6例(7.5%),90天死亡8/80(10%),活检至死亡中位间隔38天(四分位距19.7-86天)。

证据类型、等级与局限

  • 证据类型:单中心、回顾性、观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,对于存在急性肾损伤且合并出血风险因素的精选危重患者,经静脉肾活检安全并获得高诊断阳性率,即使存在多项出血风险因素。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Transvenous renal biopsy is an alternative way to obtain kidney samples from patients with bleeding risk factors (e.g., antiplatelet therapy and anticoagulation or coagulation disorders). This study was undertaken to determine the safety and diagnostic yield of transvenous renal biopsy of critically ill patients.

DESIGN: Monocenter, retrospective, observational cohort study.

SETTING: A 26-bed French tertiary ICU.

PATIENTS: All patients undergoing in-ICU transvenous renal biopsy between January 2002 and February 2018.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Eighty patients (male/female sex ratio, 0.95; mean ± SD age, 47.3 ± 18.3 yr) were included. A histologic diagnosis was obtained for 77 patients (96.3%), with acute tubular necrosis being the most frequent: 23 (29.9%). A potentially treatable cause was found for 47 patients (58.7%). The numbers of patients with 0, 1, 2, or 3 factors (i.e., antiplatelet therapy, thrombopenia [< 150 G/L], and preventive or curative anticoagulation) at the time of the biopsy were, respectively: seven (8.8%), 37 (46.2%), 31 (38.7%), and five (6.3%). Four (5%) and two (2.5%) patients, respectively, had renal hematoma and macroscopic hematuria; none required any specific treatment. Six patients (7.5%) died in-ICU, and 90-day mortality was 8 of 80 (10%). No death was related to transvenous renal biopsy, and median biopsy-to-death interval was 38 days (interquartile range, 19.7-86 d).

CONCLUSIONS: Based on this cohort of ICU patients with acute kidney injury, transvenous renal biopsy was safe and obtained a high diagnostic yield for these selected critically ill patients, even in the presence of multiple bleeding risk factors.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. de Chambrun MP, Cluzel P, Brocheriou I, et al. Transvenous Renal Biopsy of Critically Ill Patients: Safety and Diagnostic Yield. Crit Care Med. 2019. PMID: 30608282. doi:10.1097/CCM.0000000000003634

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。